|
Monday 8th December 2025 |
Text too small? |
Rua Bioscience is pleased to provide an update on the progress of its pro rata rights offer currently open to eligible shareholders.
To date the Company has received commitments for over $1.5 million from existing shareholders, with a total of $2 million on offer. This demonstrates strong support for Rua’s strategy and the objectives of the capital raise. These commitments reflect the confidence of shareholders in the Company’s commercial progress, operational execution, and long-term growth ambitions in the global medicinal cannabis sector.
The pro rata rights offer remains open until the end of day on Friday, 12 December 2025. Any shareholder that wishes to participate should do so before this date. Full details of the offer, including the timetable and instructions on how to take up rights, are set out in the Offer Document available at www.ruabio.com/capital-raise-november-2025.
Funds raised through the Rights Offer will be applied to working capital and marketing activities to support Rua’s growth opportunities, including the launch and commercialisation of new products across key international markets such as Germany, Australia, the United Kingdom, and Czechia.
ENDS
No comments yet
AIR - Air New Zealand market update
May 14th Morning Report
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million
SML - Resignation of Synlait Director
FBU - Sale of Laminex Cheltenham property
CVT - Comvita Achieves Minimum Capital Raise Requirement
Devon Funds Morning Note - 04 May 2026